The Competition and Consumer Commission of Singapore (CCS) has approved Zuellig Pharma Holdings Pte Limited’s proposed acquisition of certain assets from Eli Lilly and Company. The decision, announced on 5 May 2026, follows an assessment that the transaction will not significantly reduce competition in Singapore’s market for erectile dysfunction (ED) medications.
CCS’s evaluation of the acquisition proposal and feedback from third parties concluded that the market would stay competitive. The commission noted that Cialis, a prescription medication for ED, is not essential for distributors aiming to sell other products. Furthermore, Zuellig Pharma will not have the ability to favour Cialis over other ED medications it distributes.
This clearance ensures that the acquisition will not disrupt the supply and distribution dynamics of ED medications in Singapore. The CCS’s decision reflects its commitment to maintaining a competitive market environment, allowing consumers to benefit from a variety of choices and competitive pricing.
